atai Life Sciences, a Berlin, Germany-based clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, closed a $157m Series D financing round.
The round was led by existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and joined by Woodline Partners LP, with participation from existing and new investors including Fearless Ventures, Falcon Edge Capital, Pura Vida Pro LLC, Catalio Capital Management, Michael Auerbach’s Subversive Capital and Highline Capital.
The company intends to use the funds to expand and develop its diverse drug candidate pipeline and enabling technologies, to continue advancing its current clinical developments, as well as scale its team in order to continue delivering key milestones.
Led by Angermayer and Florian Brand, CEO & co-founder, atai Life Sciences is a clinical-stage biopharmaceutical company dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential.
The company also has offices in New York.